1570P - Dynamic changes in imaging biomarkers on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) are associated with survival outcomes in patients with concurrent chemoradiotherapy for esophageal cancer

Background

Patients with Esophageal Cancer (EC) have variable responses to (chemo)radiotherapy. A reliable early prediction of outcomes allows for enhancing treatment efficacy and follow-up monitoring. DCE-MRI can provide information regarding tumor perfusion and permeability and has shown prognostic value in certain tumor types. Our aim was to investigate the potential application of DCE-MRI parameters as predictors for progression-free (PFS) and overall survival (OS) inpatients with EC treated with concurrent chemoradiation (CRT).

Methods

This study involved fifty-two patients with esophageal cancer and treated with CRT. The patients underwent DCE-MRI before CRT (pre-CRT) in three weeks and three weeks after starting CRT (post-CRT). Patients were grouped into high and low risk groups according to the cut-off value of best OS and PFS respectively. The correlations between quantitative parameters of DCE-MRI (pre-K^trans, post-K^trans and the changes and ratios of parameters (ΔiK^trans, riK^trans), and OS/PFS were calculated and compared between two-time frames in two groups, respectively. The K-M method was used to calculate the survival curve, and the log-rank method was used to compare differences in the survival curves.

Results

The level of pre-CRT K^trans was positively associated with OS (cutoff value=70.53/min, p=0.113) and PFS (cutoff value=70.53/min, p=0.026). The level of post-CRT K^trans was impaired associated with OS (cutoff value=45.60/min, p=0.001) and PFS (cutoff value=45.60/min, p=0.003). Level of riK^trans was impaired associated with OS (cutoff value=0.374, p=0.024) and PFS (cutoff value=0.374, p=0.040). The level of ΔiK^trans was impaired associated with OS (cutoff value=4.5/min, p=0.048) and PFS (cutoff value=0.595/min, p=0.056).

Conclusions

This study suggests an important role for DCE-MRI parameter K^trans as a predictor of outcome in Esophageal Cancer patients treated with CRT.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Y. Liu.

Funding

NA.

Disclosure

All authors have declared no conflicts of interest.